A subset of colorectal cancers responds to anti-epidermal growth factor receptor ( anti-EGFR ) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the Cancer Discovery.
Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitors.
The MET gene is known to be amplified in about 10% of colorectal cancers, and is associated with worse prognosis.
A subset of metastatic colorectal cancers responds to the anti-EGFR drugs Cetuximab ( Erbitux ) and Panitumumab ( Vectibix ), but almost always develops resistance within several months of the initiation of therapy.
Mutations in genes related to EGFR signaling, including KRAS, BRAF and NRAS, account for about 60% of the cases that develop resistance; the cause of resistance in tumors without these mutations is unknown.
Alberto Bardelli, at the University of Torino in Italy, and his colleagues analyzed tumors from seven patients who developed resistance subsequent to anti-EGFR therapy, and identified three who did not have the previously known mutations. Using next-generation sequencing, they demonstrated amplification of the MET gene in these three tumor samples.
Blood samples collected at regular intervals during treatment with anti-EGFR therapy until relapse were available for two of the three patients. The researchers were able to detect MET amplification in the blood, and they demonstrated it occurred prior to relapse. The ability to detect MET amplification in blood provides a noninvasive, highly sensitive method for monitoring and predicting drug resistance and tumor recurrence.
Using xenopatients ( patient-derived, drug-resistant colorectal cancers grafted and grown in mice ) the researchers identified a novel, biologically distinct subset of tumors that were resistant to anti-EGFR drugs and did not have alterations in KRAS, BRAF or NRAS but carried MET amplification. The researchers further confirmed the overexpression of the MET gene and MET protein in these tumors using special techniques called fluorescent in situ hybridization and immunohistochemistry.
As a next step, the researchers tested the efficacy of the clinically approved MET inhibitor Crizotinib ( Xalkori ) in two xenopatients.
A MET inhibitor in combination with an anti-EGFR drug caused maximum antitumor activity and sustained response in both xenopatients.
According to Bardelli, MET inhibitors, alone or in combination with anti-EGFR therapies, offer novel therapeutic opportunities. ( Xagena )
Source: American Association for Cancer Research, 2013